Richard Goldberg
May 30, 2025, 10:47
Richard Goldberg: Agenus Anticipates Interacting with FDA with New Data Coming at ESMO-GI 2025
Richard Goldberg, Chief Development Officer at Agenus, shared a post on LinkedIn:
“As many of you know, I’ve come out of retirement and joined Agenus as its Chief Development Officer because of the alarming rise in the incidence of early onset colorectal cancer, and also because of the promise that I see in the rapidly growing field of immuno-oncology, and, in particular, the potential roles for Agenus’ agents botensilimab and balstilimab.
The basket study which Dr. Chalabi presented at AACR showed promising data on this combination. And last week’s Make America Healthy Again report only confirms the concerning rise in the incidence of colorectal cancer in younger people.
All patients, and especially these younger patients, deserve new and innovative treatments that will potentially spare them from coping with life-changing side effects. They are clamoring for better options than chemotherapy, radiation, and surgery.
As a quick update on the company: we are anticipating interacting with the FDA as data from phase I and II studies mature and we are planning to present new data at this year’s ESMO-GI Congress in Barcelona, which takes place from July 2-5. It is a busy time at Agenus, but certainly a very exciting time.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 8, 2025, 20:27
Jul 8, 2025, 18:55